InvestWiser
BioArctic AB (publ)
BIOA-B · Nasdaq Stockholm · Healthcare
305.20SEK
−0.6%last day
Price as of 2 October 2026
Performance
1 month
−11.8%
1 year
+3.0%
3 years, per year
+3.3%
5 years, per year
+16.5%
Largest fall, 3 years
−63.0%
Below the peak now
−18.7%
Volatility, 1 year
42.8%
Return with dividends reinvested.
Key figures
P/E
247.7
P/B
13.0
Dividend yield
0.7%
Return on equity
+5.2%
Net margin
+10.5%
Market value
2.7 bn USD
Quality, value and trend
Where BioArctic stands against every Nordic stock today. 100 is best.
55
Profitability and a sound balance sheet over time. Better than 55% of Nordic stocks.
6
The price measured against earnings, assets and cash flow. Better than 6% of Nordic stocks.
47
The price development over the past year. Better than 47% of Nordic stocks.
22
Quality, value and trend together. Better than 22% of Nordic stocks.
About BioArctic
BioArctic AB (publ) is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 150 employees.
BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of biological drugs, such as antibodies that address high unmet medical needs. The company's therapeutic areas encompass neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and ALS. In addition, it offers lecanemab for intravenous treatment.
See the full analysis in InvestWiser.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
See the full analysis